Chemotherapy for good-risk germ-cell tumors Journal Article

Authors: Ryan, C. J.; Bajorin, D. F.
Article Title: Chemotherapy for good-risk germ-cell tumors
Abstract: Patients with good-risk germ-cell tumors have a high likelihood of cure with an approach that integrates cisplatin-based chemotherapy, surgery, radiation, and observation. This article addresses risk group allocation as well as the controversies regarding the composition, number of cycles, and dosages of chemotherapy regimens used in this population. Recent data from randomized trials demonstrate that carboplatin is inferior to cisplatin and that the dose of etoposide should be 500 mg/m2 per course. Bleomycin remains controversial in good-risk germ-cell tumors, but the literature suggests that both E500P for four cycles or BE500P for three cycles may be considered standard. Copyright 2002, Elsevier Science (USA). All rights reserved.
Keywords: treatment outcome; clinical trial; neutropenia; review; cisplatin; cancer risk; dose response; drug efficacy; risk benefit analysis; antineoplastic agents; chemotherapy; cancer staging; neurotoxicity; antineoplastic agent; carboplatin; lung toxicity; nephrotoxicity; bone marrow suppression; etoposide; thrombocytopenia; antineoplastic combined chemotherapy protocols; drug administration schedule; antineoplastic agents, phytogenic; risk factors; vinblastine; chemotherapy induced emesis; testicular neoplasms; bleomycin; antibiotics, antineoplastic; germ cell tumor; raynaud phenomenon; ototoxicity; germinoma; germ-cell tumors; humans; human; male; priority journal
Journal Title: Seminars in Urologic Oncology
Volume: 20
Issue: 4
ISSN: 1081-0943
Publisher: W.B. Saunders Co.  
Date Published: 2002-11-01
Start Page: 244
End Page: 250
Language: English
DOI: 10.1053/suro.2002.37208
PUBMED: 12489057
PROVIDER: scopus
Notes: Export Date: 14 November 2014 -- Source: Scopus
Citation Impact
MSK Authors
  1. Dean Bajorin
    582 Bajorin
  2. Charles Ryan
    9 Ryan